BMEA Latest News, Press Relases and Analysis

All

Press Releases

14 days ago - By: Chartmill - Mentions: NCT AEO ACHC CTW ...

Which stocks are moving after the closing bell on Tuesday?

7 days ago - By: Biomea Fusion, Inc.

Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025

7 days ago - By: Biomea Fusion, Inc.

Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025

11 days ago - By: Biomea Fusion, Inc.

Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

11 days ago - By: Biomea Fusion, Inc.

Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

15 days ago - By: Biomea Fusion, Inc.

Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

15 days ago - By: Biomea Fusion, Inc.

Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

15 days ago - By: Biomea Fusion, Inc.

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

15 days ago - By: Biomea Fusion, Inc.

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

22 days ago - By: Biomea Fusion, Inc.

Biomea Fusion to Participate at Upcoming Investor Conferences

22 days ago - By: Biomea Fusion, Inc.

Biomea Fusion to Participate at Upcoming Investor Conferences

a month ago - By: Biomea Fusion, Inc.

Biomea Fusion to Participate at Jefferies London Healthcare Conference

a month ago - By: Biomea Fusion, Inc.

Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025

a month ago - By: Biomea Fusion, Inc.

Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025

a month ago - By: Biomea Fusion, Inc.

Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights

a month ago - By: Biomea Fusion, Inc.

Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights

2 months ago - By: Biomea Fusion, Inc.

Biomea Fusion to Present Poster Presentations at ObesityWeek®2025

2 months ago - By: Biomea Fusion, Inc.

Biomea Fusion to Present Poster Presentations at ObesityWeek®2025

2 months ago - By: Biomea Fusion, Inc.

Biomea Fusion Announces First Patient Dosed in Phase I Study of BMF-650 a Next-Generation Oral GLP-1 Receptor Agonist

2 months ago - By: Biomea Fusion, Inc.

Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series

2 months ago - By: Biomea Fusion, Inc.

Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series

2 months ago - By: Benzinga - Mentions: SNWV CLRB APVO SPRB ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

2 months ago - By: Benzinga

Biomea Fusion Stock Plummets Following Public Offering, Diabetes Study

2 months ago - By: Biomea Fusion, Inc.

Biomea Fusion Announces Pricing of Public Offering of Securities

2 months ago - By: Biomea Fusion, Inc.

Biomea Fusion Announces Pricing of Public Offering of Securities

2 months ago - By: Biomea Fusion, Inc.

Biomea Fusion Announces Proposed Public Offering of Securities

2 months ago - By: Biomea Fusion, Inc.

Biomea Fusion Announces Proposed Public Offering of Securities

2 months ago - By: Biomea Fusion, Inc.

Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations

2 months ago - By: Biomea Fusion, Inc.

Biomea Fusion Announces Positive 52-Week Results from Phase II COVALENT-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations

3 months ago - By: Biomea Fusion, Inc.

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Biomea Fusion, Inc.

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Biomea Fusion, Inc.

Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update

3 months ago - By: Biomea Fusion, Inc.

Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update

BIOMEA FUSION INC (BMEA) Stock News

BMEA Latest News, Press Relases and Analysis